Most current allergy biologics block a cytokine, its receptor, or IgE itself.
Five papers in the October 2026 issue of JACI (Vol. 158, Issue 4) point one step deeper — at the cells and signaling switches that decide whether an allergic response happens at all. None is a clinical treatment yet, but together they map where the next generation of targets may come from.
Siglec-6 — nanocarriers carrying midostaurin and targeted to Siglec-6 selectively eliminated human mast cells, with limited off-target effects.
SMURF2 — an intracellular amplifier of FcεRI signaling; mast-cell knockout attenuated anaphylaxis and airway disease.
BCR restraint of IgE — B-cell receptor ligation selectively inhibits IgE class-switch recombination — a built-in checkpoint on IgE production.
KIT+ ILC2 — a poised, plastic precursor state, maintained by IL-2/IL-7 via STAT5 and enriched for asthma and autoimmunity risk variants.
SPRR2A-CSTA — an IL-17A-driven epithelial axis behind steroid-resistant allergic rhinitis; serum levels separated resistant from responsive patients.
References:
J Allergy Clin Immunol. 2026;158(4) — Thames et al., pp. 1073-1084; Liang et al., pp. 1101-1116; Wade-Vallance et al., pp. 1085-1100; Olsthoorn et al., pp. 1117-1132; Xie et al., pp. 994-1009.